ICARE Social Media Post December 2023

Tamoxifen and Breast Cancer Risk in BRCA Mutations

In a recent study among female BRCA1/2 carriers, including ICARE participants, researchers explored the impact of using tamoxifen and/or raloxifene on breast cancer risk. 👩‍🔬

After almost 7 years of follow-up, only 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% of those in the non-user group. These findings suggest that chemoprevention through the use of tamoxifen and/or raloxifene may help reduce the risk of breast cancer in BRCA1/2 carriers. However, more studies with longer follow-up are needed to confirm the results. 🔬📚

Learn more at: https://pubmed.ncbi.nlm.nih.gov/37432545/

Reference: Kotsopoulos, et al. Breast Cancer Res Treat. 2023;201(2):257-264. PMID: 37432545.

Permanent link to this article: https://inheritedcancer.net/post120523/